NASDAQ: AVBPArrivent Biopharma Inc Stock
$18.14+0.24 (+1.34%)
Updated Apr 17, 2025
AVBP Price
$18.14
Fair Value Price
$2.36
Market Cap
$617.05M
52 Week Low
$14.35
52 Week High
$36.37
P/E
-7.09x
P/B
2.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$80.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$70M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVBP Overview
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVBP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVBP
Ranked#194 of 463
Ranked#194 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important AVBP news, forecast changes, insider trades & much more!
AVBP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVBP ($18.14) is overvalued by 670.21% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVBP ($18.14) is not significantly undervalued (670.21%) relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVBP due diligence checks available for Premium users.
Valuation
AVBP fair value
Fair Value of AVBP stock based on Discounted Cash Flow (DCF)
Price
$18.14
Fair Value
$2.36
Overvalued by
670.21%
AVBP ($18.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVBP ($18.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.09x
Industry
-177.72x
Market
27.98x
AVBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.39x
Industry
4.05x
AVBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.6M
Profit Margin
0%
AVBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$274.9M
Liabilities
$17.3M
Debt to equity
0.07
AVBP's short-term assets ($226.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVBP's short-term assets ($226.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.2M
Investing
-$192.5M
Financing
$55.0k
AVBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVBP vs Biotech Stocks
Arrivent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.